The Respiratory Department at St James’s hospital  run a number of both investigator-led and industry centered drug trials in respiratory in conjunction with the CRF.

Current Trials & Studies
Study Name Study TitleStudy TypeSponsorSponsor Type
Insmed (ASPEN)A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, MultiCenter Study to Assess the Efficacy, Safety, and Tolerability of INS1007 Administered Once Daily for 52 Weeks in Subjects with Non-CysticFibrosis Bronchiectasis Clinical Trial (2020-003688-25) (NCT04594369) InsmedCommercial: Industry
GSK3511294-Nimble A 52-week, randomised, double-blind, double-dummy, parallel group, multicentre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 compared with mepolizumab or benralizumab Clinical trial (NCT04718389)GSK Commercial: Industry
BAL dccrAirway Gene Expression Profiling and Immune Responses to Lung Disease (BAL)Observational-non invasiveN/ANon-commercial: Academic
Past Trials & Studies
Study NameStudy TitleStudy TypeSponsorSponsor Type
Thoracic Biobank Estbalishment of a Thoracic Biobank to use in molecular and Cellular Studies Prospective Cohort St. James's Foundation Non-commercial: Hospital
MA39297An international trial to characterize the disease behaviour of idiopathic pulmonary fibrosis and interstitial lung disease during the peri-diagnostic periodClinical Trial (NCT03261037)F Hoffmann- La Roche LtdCommercial: Industry
LusterA 52 week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthmaClinical Trial (NCT02555683) (2015-002553-35)Novartis Pharma UK LtdCommercial: Industry
GALACTIC-1A randomized, double-blind, multicentre, parallel, placebo-controlled study in patients with idiopathic pulmonary fibrosis (IPF) investigating the safety and efficacy of TD139, a dry powder, inhaled galectin-3 inhibitorClinical Trial (NCT03832946) (2018-002664-73) Galecto Biotech ABIndustry
CrystalCrystal - A prospective, multicentre, 12 week, randomized open label study to evaluate the efficacy and safety of glycopyrronium (50 microgrms o.d.) or indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 micrograms o.d.) regarding symptoms and health status in patients with moderate chronic obstructive pulmonary disease (COPD) switching from treatment with any standard COPD regimenClinical trial (NCT01985334) NovartisIndustry
PalladiumA multi-centre, randomised, 52 week treatment, double-blind, triple-dummy, parallel-group study to assess the efficacy and safety of QMF149 compared with mometason furoate in patients with asthmaClinical trial (NCT02554786) Novartis Pharma UK LtdIndustry
IPF/Sarcoidosis IPF/Sarcoidosis (DCCR) Observational with radiology or blood tests DCCR Non-commercial: Academic
IGRA IGRA (DCCR) Observational with radiology or blood tests HSE - Health Protection Surveillance Centre Non-commercial: Academic
INCA Inhaler Compliance in Asthma (INCA) Medical device study (NCT01529697) Health Research Board Non-commercial: Academic